ONCY

Business Context and Reporting Period

Company: Oncolytics Biotech Inc.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2007
Business Overview: Oncolytics is a development-stage biopharmaceutical company focused on the discovery and development of REOLYSIN®, an oncolytic virus therapy targeting cancer cells with an activated Ras pathway. The company has no commercial product sales and relies on equity financing to fund research and development (R&D), clinical trials, and manufacturing process development.

Key Financial Metrics

Note: All figures are in Canadian Dollars (Cdn$). The company reported no debt as of December 31, 2007, following the fair value adjustment of a loan from the Alberta Heritage Foundation.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately $1.34 million (9.4%) from 2006 to 2007, driven primarily by higher R&D expenses.
• R&D Expenses: Total R&D expenses rose to $11.32 million in 2007 from $10.54 million in 2006. This increase was largely due to higher clinical trial expenses ($3.90 million vs. $2.73 million) as the company expanded its trial portfolio.
• Financing Activity: In 2007, the company raised approximately $12.11 million through a public offering of 4.6 million units (common shares and warrants). This contrasts with minimal equity raises in 2006 ($241,400 from option exercises).
• Debt Elimination: The $150,000 loan from the Alberta Heritage Foundation was reclassified to fair value upon the adoption of new financial instrument standards, resulting in a $150,000 reduction in the deficit and the removal of the liability from the balance sheet.
• Asset Base: Total assets decreased by approximately $2.78 million, primarily due to the drawdown of short-term investments to fund operations, despite the cash infusion from the equity offering.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Cash Burn Rate: Management estimated the monthly cash usage for 2007 at approximately $1.4 million. For 2008, the estimated monthly cash usage is projected to increase to $1.66 million.
• Liquidity Position: As of December 31, 2007, the company held approximately $25.2 million in cash and short-term investments. Management believes these resources are sufficient to fund operations well into 2009.
• Development Goals: The company plans to continue enrolling patients in clinical trials throughout 2008, including Phase II trials for sarcoma and melanoma. Manufacturing efforts will focus on scaling up production to 100-litre batches and transferring technology to a U.S. toll manufacturer.

Risks and Contingencies

• Development Risk: REOLYSIN® is in the research and development stage. There is no assurance that clinical trials will demonstrate safety and efficacy sufficient for regulatory approval.
• Financing Risk: The company has a history of losses and no operating revenues. It will require additional financing in the future to fund R&D and commercialization. There is no guarantee that additional capital will be available on acceptable terms.
• Manufacturing Dependence: The company relies on third-party contract manufacturers. Disruption in supply from the primary U.K. manufacturer could delay clinical trials.
• Regulatory Risk: Approval by the FDA, Health Canada, and other authorities is required before commercial sales can begin. Regulatory requirements may change or become more stringent.
• Intellectual Property: The company's success depends on maintaining patent protection. Competitors may challenge patents or develop superior technologies.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the projected $1.66 million monthly burn rate for 2008 against actual quarterly results to assess the sufficiency of the $25.2 million cash balance.
• Clinical Trial Progress: Monitor enrollment rates and interim data releases for the Phase II Sarcoma trial (REO 014) and the NCI-sponsored Melanoma trial to validate the path to regulatory approval.
• Manufacturing Transfer: Confirm the successful completion of the technology transfer to the U.S. toll manufacturer and the ability to scale production to 100-litre batches as planned.
• Equity Dilution: Assess the potential dilution from the 4.22 million outstanding warrants and 3.87 million outstanding stock options if exercised.
• Regulatory Milestones: Track the status of the Investigational New Drug (IND) applications and any communications with the FDA or Health Canada regarding the REOLYSIN® program.